Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
Myeloma
MYELOMA
FEATURE
LATEST ARTICLES
Symptom Burden Level in Multiple Myeloma Defined by Clinical, Other Characteristics
Researchers conducted a cross-sectional study to identify patterns of demographic and clinical characteristics that corresponded to level of symptom burden in patients with multiple myeloma.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Health-Related QOL Not Addressed in Standard Care of Patients With Multiple Myeloma
Researchers sought to determine which QOL tools are being used as part of routine care for patients with multiple myeloma.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Subcutaneous Daratumumab Linked to Shorter Clinic Times for Patients With Multiple Myeloma
Researchers sought to determine whether a different administration of daratumumab would lead to shorter clinic times for patients with multiple myeloma.
Vagal Nerve Activity as Prognostic Factor for Multiple Myeloma, Relapsed/Refractory DLBCL
Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively.
Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.
Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma
Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.
MRD Conversion During Maintenance Predicts Progression-Free Survival in Myeloma
Researchers sought to determine whether conversion of MRD status during maintenance would affect risk of disease progression in patients with MM.
Ide-Cel Bests Standard Care in Relapsed/Refractory Multiple Myeloma
Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.
Elotuzumab Plus Pomalidomide and Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether elotuzumab with pomalidomide and dexamethasone would improve survival in relapsed/refractory multiple myeloma.
Patients With Double-Hit Multiple Myeloma Have Inferior Outcomes After Transplant
The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.
Efficacy and Safety of Ide-Cel Confirmed in Real-World Multiple Myeloma Population
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Daratumumab Extends OS in Relapsed/Refractory Multiple Myeloma
Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.
KCd Inferior to Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Researchers sought to determine whether a transplant-free regimen of KCd with carfilzomib maintenance would have similar efficacy to HSCT in multiple myeloma.
Novel Risk Prediction Tool May Identify Patients With Multiple Myeloma at a High Risk of Venous Thromboembolism
Researchers sought to determine whether the PRISM score would be able to identify patients with multiple myeloma at a high risk of VTE.
Dexamethasone-Sparing Regimen Shows Promise in Frail Patients With MM
A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.
Circulating Leukocyte DNA Methylation Level May Be a Novel Biomarker in Multiple Myeloma
Researchers sought to determine whether DNA methylation in PBMCs could be a novel biomarker in multiple myeloma.
Teclistamab Plus Daratumumab and Lenalidomide Shows Promise in Rel/Ref Multiple Myeloma
Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.
Talquetamab Elicits Responses in Relapsed/Refractory Multiple Myeloma
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
Sarcopenia Predicts Negative Outcomes in Newly Diagnosed Myeloma
Researchers sought to determine whether sarcopenia would be predictive of survival in patients with newly diagnosed multiple myeloma.
Threshold of Circulating Tumor Cells Indicates Higher Risk in Newly Diagnosed Multiple Myeloma
Researchers sought to characterize a subset of patients with newly diagnosed multiple myeloma with features similar to those seen with primary plasma cell leukemia.
Clinical Trials Do Not Accurately Represent Patient Diversity in Hematologic Cancers
Researchers sought to determine whether patient groups are accurately represented in clinical trials leading to the approval of drugs for patients with leukemia or MM.
Loss of 2q37 Linked to Immunomodulatory Drug Resistance in Multiple Myeloma
Researchers sought to determine whether there was a connection between loss of the 2q37 chromosomal region and resistance to immunomodulatory drugs in MM.
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Older MM Patients Have More Advanced Disease, Worse Outcomes in Real World vs RCTs
Multiple myeloma patients age 75 and older present with more advanced disease and have worse outcomes in the real world than in clinical trials, a study suggests.
Ciltacabtagene Autoleucel Improves Health-Related Quality of Life in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether ciltacabtagene autoleucel would result in durable responses in patients with R/R multiple myeloma.
Targeting SENP-1, SRC-3 May Help Overcome Chemoresistance to Proteasome Inhibitors in Myeloma
Researchers sought to determine whether hypoxia would induce chemoresistance to proteasome inhibitors in patients with multiple myeloma.
Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
The approval was based on data from the MajesTEC-1 study which included 110 adults with relapsed or refractory multiple myeloma who had previously received ≥3 prior therapies.
Oncology Care Model Failed to Account for Patient and Disease Complexity, Researchers Say
Critical variables for 3 of the highest-volume cancers were not measured under the Oncology Care Model, according to researchers.
Iberdomide Plus Dexamethasone Elicits Responses in Relapsed/Refractory MM
Iberdomide plus dexamethasone demonstrated “meaningful” clinical activity in relapsed/refractory multiple myeloma, according to researchers.
HRQOL Affected by Line of Therapy, Anxiety, and Depression in Multiple Myeloma
Researchers sought to determine which characteristics influence the health-related quality of life in patients with multiple myeloma.
Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma
Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years.
Treatment Advances Have Improved Multiple Myeloma Mortality in the US
Researchers sought to determine the mortality trends for patients with multiple myeloma over the past few decades.
Access to Trials of CAR T-Cell Therapy or Bispecific Antibodies May Vary by Race
Black patients with multiple myeloma may not have equitable access to clinical trials of CAR T-cell therapy or bispecific antibodies.
Belantamab Mafodotin Yields Good Response Rate in Patients With Relapsed, Refractory Multiple Myeloma
Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma
Lower Risk of Smoldering Multiple Myeloma Progression Among African Americans
Researchers sought to determine whether there were differences in rates of progression of smoldering multiple myeloma in African American patients.
D-Rd Appears to Improve Long-Term Outcomes in Newly Diagnosed, Transplant-Ineligible Myeloma
Researchers sought to determine whether adding daratumumab to lenalidomide and dexamethasone would improve outcomes in patients with newly diagnosed, transplant-ineligible MM.
Quadruplet Therapy Shows Promising Results as Salvage Therapy for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether adding ixazomib to daratumumab, pomalidomide, and dexamethasone would be a treatment option in patients with R/R MM.
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Final results from ICARIA-MM support isatuximab plus pomalidomide and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, according to researchers.
Intensive-Dosing MPB Regimen May Improve PFS in Multiple Myeloma
Researchers sought to determine whether patients with multiple myeloma would have a survival benefit from bortezomib with melphalan.
Ixazomib After Allogeneic Transplantation Needs Further Assessment for Patients With High-Risk Multiple Myeloma
Researchers sought to determine whether patients with high-risk multiple myeloma undergoing HCT would benefit from reduced-intensity conditioning with Flu/Mel/Bort.
MRD-Guided Therapy Produces Durable Responses in Newly Diagnosed Multiple Myeloma
Quadruplet therapy guided by MRD status can produce durable responses in patients with newly diagnosed multiple myeloma, a study suggests.
Loss of Balance Is Triggering Factor for Skeletal-Related Events in Multiple Myeloma With Bone Disease
Researchers sought to determine whether a loss of balance along with associated falls could be a triggering factor for skeletal-related events in multiple myeloma.
Expression of Immune-Related Genes and Risk Stratification in Multiple Myeloma
Researchers sought to determine a risk stratification method for patients with multiple myeloma based on expression of immune-related genes.
Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether there were benefits with early use of daratumumab-based triplet therapies in patients with relapsed/refractory multiple myeloma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Myeloma
Loading... 
Loading...